Background Increases in lipid levels and cancers with tofacitinib prompted a trial of major
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …

The pathogenesis of SpA is multifactorial and involves a range of immune cell types and
cytokines, many of which utilize Janus kinase (JAK) pathways for signaling. In this review, we …

Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis …

Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis …

Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550)
or adalimumab monotherapy with placebo for the treatment of active rheumatoid …

Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550)
with placebo for the treatment of active rheumatoid arthritis (RA) in patients …

Clinical observations indicate that some autoimmune diseases, such as rheumatoid arthritis
and multiple sclerosis, frequently remit during pregnancy but exacerbate, or have their onset…

The observation in 1938 that pregnancy and jaundice ameliorate rheumatoid arthritis (RA)
prompted PS Hench to hypothesize that adrenal insufficiency was the cause of RA. These …

Objectives To compare efficacy and safety of various doses of tofacitinib, an oral Janus
kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic …